Hypertension and Diabetes Mellitus

Login or register to view PDF.
Citation
European Cardiovascular Disease 2006 - Issue 1;2006:2(1):1-7
DOI
http://dx.doi.org/10.15420/ecr.2006.1.1a

There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. 1 The epidemic of diabetes will continue to rise as there is growing prevalence of obesity in children, which predisposes to diabetes.2 There is considerable evidence for an increased prevalence of hypertension in diabetic persons.3 In a large prospective cohort study that included 12,550 adults, the development of type 2 diabetes was almost 2.5 times as likely in persons with hypertension than in their normotensive counterparts.3,4 Similarly, evidence points to increased prevalence of hypertension in diabetic persons.3,5 Moreover, each pathophysiological disease entity serves to exacerbate the other.3,6 Both hypertension and diabetes predisposes to the development of cardiovascular disease (CVD) and renal disease.7,8 Subjects with diabetes are at about 60% increased risk of early mortality.8,9 The age-adjusted relative risk of death due to cardiovascular events in persons with type 2 diabetes is three-fold higher than in the general population. The presence of hypertension in diabetic patients substantially increases the risks of coronary heart disease, stroke, nephropathy and retinopathy.5,10,11 Indeed, when hypertension coexists with diabetes, the risk of CVD is increased by 75%, which further contributes to the overall morbidity and mortality of an already high-risk population.5,12 Generally, hypertension in type 2 diabetic persons clusters with other CVD risk factors such as microalbuminuria, central obesity, insulin resistance, dyslipidaemia, hypercoagulation, increased inflammation and left ventricular hypertrophy.5 This clustering risk factor in diabetic patients ultimately results in the development of CVD, which is the major cause of premature mortality in patients with type 2 diabetes.

Pathophysiology of Hypertension in the Diabetic Patient

Epidemiologic studies provide evidence for co-existence of hypertension and diabetes and possibly point towards a common genetic and environmental factor promoting both diabetes and hypertension. Similarly, clustering of hypertension, insulin resistance or frank type 2 diabetes, hyperlipidaemia and central obesity have been documented in several populations.13 Insulin resistance, increased tissue inflammation and reactive oxygen species (ROS) production resulting in endothelial dysfunction, increased tissue renin- angiotensin-aldosterone system (RAAS) and increased sympathetic nervous system (SNS) activity have all been implicated in this complex pathophysiology of diabetes and hypertension.

Diabetes, Insulin Resistance and Hypertension - A Complex Interrelated Process and the Crucial Role of RAAS

It is estimated that about 25-47% of persons with hypertension have insulin resistance or impaired glucose tolerance.14 With insulin resistance there are impaired biological and physiological tissue responses to insulin. The relationship of insulin resistance, diabetes and hypertension is complex and interrelated. Untreated patients with essential hypertension have higher fasting and postprandial insulin levels than age- and sex-matched normotensive persons, regardless of body mass; a direct correlation between plasma insulin levels and blood pressure (BP) exists.5,15 Interestingly, the relationship between hyperinsulinaemia and hypertension is not seen in secondary hypertension.15 This indicates that insulin resistance and hyperinsulinaemia are not consequences of hypertension, but rather a genetic predisposition that acts as a fertile soil for both diseases. This notion is supported by the observation that there is abnormal glucose metabolism in the offspring of hypertensive parents.15,16 Thus, there is a strong association between hypertension, diabetes and insulin resistance. There is also a strong association between upregulation of RAAS, hypertension and diabetes.17-19 This upregulation of RAAS results in enhanced generation of ROS and may explain impaired glucose utilisation as well as hypertension associated with insulin resistance and type 2 diabetes.20 It has been proposed that increased autocrine/paracrine activity of angiotensin II (ANG II) results in diminished action of insulin and insulin growth factor-1 (IGF-1) signalling through the PI3K/Akt pathway, resulting in inhibition of mechanisms involved in the vasodilator and glucose transport properties of insulin and IGF-121,20 (see Figure 1 and 2). Insulin activates the PI3K/Akt system in skeletal muscle, adipose, and myocardial tissues and initiates translocation of the GLUT4 glucose receptor to the cell membrane. The unregulated ANG II acts through its receptor (AT1R) and results in formation of ROS and the activation of low-molecular- weight G proteins such as Rho A.20 Activation of these small G proteins and consequent enhancement of the generation of ROS inhibits insulin/IGF-1 actions mediated through PI3K/Akt signalling including activation of endothelial nitric oxide (NO) synthase (eNOS) activity, Na+ pump activation, and Ca2+-myosin light chain (MLC) desensitisation.20

Similar RAAS-mediated increases in oxidative stress are likely contribute to insulin resistance in skeletal muscles. This is supported by findings that ROS are increased in skeletal muscle from Ren-2 rats that over-express tissue ANG II, and that this effect is abolished when the animals are treated with an AT1R blocker.22 This and numerous other studies have shown that therapy with angiotensin-converting enzyme inhibitors (ACE-I) decreases the progression to type 2 diabetes in high-risk patients.5,23-25 These and other studies imply the critical role played by RAAS and usefulness of ACE-I in the treatment of diabetes and hypertension.26

Activation of the RAAS also results in increased aldosterone secretion from the adrenal gland and resultant salt retention and volume expansion and consequent hypertension. Further, aldosterone also contributes to hypertension by enhancing SNS activity, decreasing parasympathetic activity, and reducing baroreceptor sensitivity.27 Other effects of aldosterone in kidney, besides the salt retension, include increased extracellular matrix deposition by glomerular cells, leading to glomerulosclerosis and hypertension.27

Blockade of the aldosterone receptor in the Randomized Aldactone Evaluation Study (RALES) using spironolactone in patients with chronic moderate to severe heart failure, corresponding to New York Heart Association (NYHA) class 3 and 4, reduced mortality by 30%.28 More recently, the selective aldosterone receptor antagonist eplerenone in heart failure patients showed a similar decrease in mortality with fewer side effects.29

Other possible causes of hypertension with diabetes and insulin resistance/hyperinsulinaemia include activation of the sympathetic nervous system, increased renal tubular sodium retention, elevated intracellular calcium concentration and vascular smooth muscle cell proliferation and atherosclerosis, and impaired NO metabolism in skeletal muscle.7,30-35 Another mechanism is the upregulation of vascular AT1Rs by post-transcriptional mechanisms enhancing the vasoconstrictive and volume-expanding actions of the RAAS.36 Some studies even suggest that excess levels of insulin can interfere with compliance of the great vessels and decrease the ability of the aorta to reflect aortic waves.37 Therapy targeted at insulin resistance, such as aerobic exercise or thiazolidenedione drugs, results in a decrease in BP.38,39

Management

In patients with diabetes, the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends a target BP of <130/80mmHg in order to prevent death and disability associated with high BP. Once hypertension is detected both pharmacological and non-pharmacological interventions should be implemented. Instituting lifestyle modifications is paramount, along with medical therapy at the earliest detection of the pre-hypertensive patient.

Lifestyle Changes

The first objective in any hypertensive diabetic should be to initiate lifestyle changes. These changes should include an improved diet, regular physical activity, weight management and cessation of smoking. Weight loss has shown to be an effective therapy in hypertension management. Moreover, studies have shown that modest weight loss can lower or even eliminate the need for antihypertensive medication.40 Patients should be advised to adopt the Dietary Approach to Stop Hypertension (DASH) eating plan, consisting of a low sodium, high potassium, low calorie (800-1,500kcal/day) and high fibre diet, as it is shown to be effective in lowering BP.41 Coupled with diet, increased physical activity, such as walking for 30-45 minutes three to five days a week, has been shown to improve lipid profiles, BP and insulin resistance.41-43

Pharmacotherapy

The JNC 7 recommendations are consistent with guidelines from the American Diabetes Association (ADA), which has also recommended that BP in diabetics be controlled to levels of 130/80mmHg or lower.44-46 Whatever the goal level, rigorous control of BP is paramount for reducing CVD mortality and morbidity.44 To achieve goal BP in diabetics, two or more drugs are usually required.47 There is convincing evidence regarding a certain class of drugs that seems to offer certain beneficial effects over others in hypertensive diabetics.

ACE-I

There is significant evidence that interruption of the RAAS can provide cardio-protective properties. Data from several large studies, such as the Captopril Prevention Project (CAPPP) and the Micro-HOPE, a sub-study of the Heart Outcomes Prevention Evaluation (HOPE) trial, have have demonstrated the cardiovascular benefits of ACE-I.23,44 ACE-I are also known to improve insulin sensitivity, retard the progression of diabetes and even prevent the development of diabetes in hypertensive patients by inhibiting RAAS.24,44 Most notably, ACE-I have also demonstrated the ability to slow progression of nephropathy in microalbuminuric, normotensive type 2 diabetes compared with other antihypertensives.48,49

After initiation of therapy with ACE-I or angiotensin receptor blockers (ARBs), monitoring of renal function and potassium is imperative.50

ARBs

Other medications receiving considerable attention in recent years are the ARBs. The antihypertensive action of ARBs is roughly equivalent to ACE-I, but does have an improved side effect profile when compared with ACE-I. Similar to ACE-I, ARBs have beneficial effects in reducing the progression of diabetes and carry other cardiovascular and renal benefits noticed in ACE-I, by virtue of its RAAS blockade.23

Several clinical trials demonstrate that ARBs also have beneficial effects on glucose metabolism that are likely independent of bradykinin-mediated mechanisms.51-54 In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan reduced the relative risk of developing type 2 diabetes by 25% when compared with the beta-blocker atenolol.53 Similarly, reduction in the relative risk of developing diabetes was noted in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) studies.52,54

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial demonstrated the advantage of an ARB, valsartan, over a calcium channel blocker (CCB), amlodipine, in reducing the relative risk of new onset diabetes by 23% in patients with hypertension aged 50 years or older.55

The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) is another double-blind multicentre study set up to investigate the role of an ARB and an ACE-I, alone or in combination, in the prevention the incidence of type 2 diabetes as a secondary end-point.56

ACE-I/ARB studies so far have assessed the incidence of type 2 diabetes as a secondary end-point. The consistent and promising results noted from these studies resulted in initiation of studies to clarify the extent by which the inhibition of RAAS can reduce the incidence of new onset diabetes. The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medications (DREAM) trial is a large international multicentre randomised, prospective double-blind controlled trial involving 4,000 people, randomised to receive either ramipril and/or rosiglitazone using a 2x2 factorial design and assessed for new onset diabetes.57 Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) is another study that evaluates the effects of an oral antidiabetic drug, nateglinide, and an ARB, valsartan, on prevention of type 2 diabetes in patients with impaired glucose tolerance. This study is similar to DREAM, but is a larger trial (7,500 subjects compared with 4,000) and investigates the effects of antidiabetic/antihypertensive therapy on the development of CVD in people with impaired glucose tolerance.58

Collectively, these on-going studies are expected to clarify the extent to which inhibition of the RAAS can reduce the incidence of new onset diabetes in patients with impaired glucose tolerance, a group that includes many Americans with essential hypertension.59

Beta-blockers

Beta-blockers can be effective antihypertensive agents in the diabetic population as part of a multi-drug regimen. Beta-blockers also find their use in diabetes patients with concomitant evidence of coronary artery disease (CAD) such as anginal symptoms, including anginal equivalents, or post-myocardial infarction (MI). The effectiveness was demonstrated in the UK Prospective Diabetes Study Group (UKPDS), where atenolol was comparable with captopril in reduction of CVD outcomes.60,61 Although these agents have been associated with adverse effects on glucose and lipid profiles and implicated in new onset diabetes in obese patients,4 they are not absolute contraindication for use in diabetic patients. In fact, carvedilol, which has both ╬▒- and ╬▓-receptor blocking properties, has been shown to induce vasodilatation and improve insulin sensitivity.62

Thiazide Diuretics

Thiazides have been shown to cause electrolyte imbalances, metabolic changes and volume contraction. Nevertheless, in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which compared a thiazide (chlorthalidone) with a calcium channel blocker (CCB) (amlodipine) or an ACE-I (lisinopril), found that the thiazide was less expensive and superior to the ACE-I or CCB in lowering the incidence of CVD in hypertensive populations.63 Therefore, ALLHAT suggests that thiazides could be considered as a first-line therapy for many diabetic patients with hypertension,63 despite the fact that they may adversely affect insulin resistance and potassium balance in some individuals.44 Indeed, utilising a thiazide diuretic in the antihypertensive repertoire has consistently been shown to improve cardiovascular outcomes, even in those with diabetes.64 Treating volume expansion with thiazide diuretics can increase the activity of the RAAS. Thus, combining a diuretic with an ACE-I or an ARB can be an effective BP-lowering combination.

CCB

It has been shown that non-dihydropyridine (ND) CCBs, such as verapamil and diltiazem, decrease proteinuria in diabetics.47 Not to the degree of ACE-I alone, but in combination therapy, NDCCBs and ACE-I have been shown to have additive effects in reducing albuminuria.49 The Syst-Eur trial with netrendipine demonstrated that intensive antihypertensive therapy for older patients with type 2 diabetes and isolated systolic hypertension eliminated the additional risk for CVD events and stroke associated with diabetes.65 In the Hypertension Optimal Treatment (HOT) trial, there was a reduction in major CVD events with diastolic BP control in patients with diabetes when felodipine was used as first-line therapy.66 Thus, CCBs are not harmful or contraindicated in hypertensive patients with diabetes and the combination of an ACE-I and a calcium antagonist is effective for the management of hypertension in diabetic patients.67

Summary

Diabetes is a growing epidemic in both the developing and developed world and more so in the former. It places an enormous burden on already sparse resources. Diabetes is known to be associated with hypertension. The presence of one increases the risk of having the other. This close relationship between diabetes and hypertension suggests a possible common genetic or pathophysiological process or both. Hypertension and diabetes are associated with increased risk of CVD and renal disease. The risk is exacerbated when both are present. It is therefore imperative that hypertension is controlled rigorously to prevent or decrease the risk of CVD and renal disease. Insulin resistance, RAAS, endothelial dysfunction, and autonomic nervous system dysfunction play an important part in the pathogenesis of hypertension and diabetes.

Therapy aimed at improving insulin sensitivity and RAAS blockade seems to offer survival benefits to diabetics with hypertension. Further work in identifying the mechanism of hypertension, diabetes and insulin resistance would shed more light on the missing link that connects these seemingly different disease processes. Ôûá

References
  1. Wild S, Roglic G, Green A, Sicree R, King H, Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030 , Diabetes Care (2004);27(5): pp. 1,047-1,053.
    Crossref | PubMed
  2. Pinhas-Hamiel O, Zeitler P, The global spread of type 2 diabetes mellitus in children and adolescents , J. Pediatr. (2005);146(5): pp. 693-700.
    Crossref | PubMed
  3. National High Blood Pressure Education Program Working Group report on hypertension in diabetes, Hypertension (1994);23(2): pp. 145-158.
    Crossref | PubMed
  4. Gress T W, Nieto F J, Shahar E, Wofford M R, Brancati F L, The Atherosclerosis Risk in Communities S. Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus , N. Engl. J. Med. (2000);342(13): pp. 905-912.
    Crossref | PubMed
  5. Sowers J R, Epstein M, Frohlich E D, Diabetes, hypertension, and cardiovascular disease: an update , Hypertension (2001);37(4): pp. 1,053-1,059.
    Crossref | PubMed
  6. Sowers J R, Epstein M, Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update , Hypertension (1995);26(6 Pt 1): pp. 869-879.
    Crossref | PubMed
  7. Sowers J R, Treatment of hypertension in patients with diabetes , Arch. Intern. Med. (2004);164(17): pp. 1,850-1,857.
    Crossref | PubMed
  8. El-Atat F, McFarlane S I, Sowers J R, Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management , Curr. Hypertens. Rep. (2004);6(3): pp. 215-223.
    Crossref | PubMed
  9. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner S M et al., Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group , Diabetes Care (1998);21(1): pp. 69-75.
    Crossref | PubMed
  10. Bakris G, Williams M, Dworkin L, Elliott W, Epstein M, Toto R et al., Preserving renal function in adults with hypertension and diabetes: A consensus approach , Journal of Kidney Diseases (2000);36(3): p. 646.
    Crossref | PubMed
  11. Sowers J R, Haffner S, Treatment of cardiovascular and renal risk factors in the diabetic hypertensive , Hypertension (2002);40(6): pp. 781-788.
    Crossref | PubMed
  12. Adler A I, Stratton I M, Neil H A W, Yudkin J S, Matthews D R, Cull C A et al., Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , BMJ (2000);321(7,258): pp. 412-419.
    Crossref | PubMed
  13. Reaven G M, Banting lecture 1988. Role of insulin resistance in human disease , Diabetes (1988);37(12): pp. 1,595-1,607.
    Crossref | PubMed
  14. Lind L, Berne C, Lithell H, Prevalence of insulin resistance in essential hypertension , J. Hypertens. (1995);13(12 Pt 1): pp. 1,457-1,462.
    Crossref | PubMed
  15. Sechi L A, Melis A, Tedde R, Insulin hypersecretion: a distinctive feature between essential and secondary hypertension , Metabolism (1992);41(11): pp. 1,261-1,266.
    Crossref | PubMed
  16. Sowers J R, Bakris G L, Antihypertensive Therapy and the Risk of Type 2 Diabetes Mellitus , N. Engl. J. Med. (2000);342(13): pp. 969-970.
    Crossref | PubMed
  17. Richey J M, Ader M, Moore D, Bergman R N, Angiotensin II induces insulin resistance independent of changes in interstitial insulin , Am. J. Physiol. Endocrinol. Metab. (1999);277(5): pp. E920-926.
    PubMed
  18. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M et al., Angiotensin II-Induced Insulin Resistance Is Associated With Enhanced Insulin Signaling , Hypertension (2002);40(6): pp. 872-879.
    Crossref | PubMed
  19. Brenner B M, Cooper M E, de Zeeuw D, Keane W F, Mitch W E, Parving H-H et al., Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy , N. Engl. J. Med. (2001);345(12): pp. 861-869.
    Crossref | PubMed
  20. Sowers J R, Insulin resistance and hypertension , Am. J. Physiol. Heart Circ. Physiol. (2004);286(5):H pp. 1,597-1,602.
    Crossref | PubMed
  21. Sloniger J A, Saengsirisuwan V, Diehl C J, Dokken B B, Lailerd N, Lemieux A M et al., Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat , Am. J. Physiol. Endocrinol. Metab. (2005);288(6): pp. E1,074-1,081.
    Crossref | PubMed
  22. Blendea M C, Jacobs D, Stump C S, McFarlane S I, Ogrin C, Bahtyiar G et al., Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression , Am. J. Physiol. Endocrinol. Metab. (2005);288(2): pp. E353-359.
    Crossref | PubMed
  23. Scheen A J, Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials , Diabetes Metab. (2004);30(6): pp. 487-496.
    Crossref | PubMed
  24. Niklason A, Hedner T, Niskanen L, Lanke J, Development of diabetes is retarded by ACE inhibition in hypertensive patientsÔÇöa subanalysis of the Captopril Prevention Project (CAPPP) , J. Hypertens. (2004);22(3): pp. 645-652.
    Crossref | PubMed
  25. Kjeldsen S E, Westheim A S, Os I, Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: LIFE, SCOPE, and VALUE , Curr. Hypertens. Rep. (2005);7(3): pp. 155-157.
    Crossref | PubMed
  26. Sowers J R, Hypertension in Type II Diabetes: Update on Therapy , J. Clin. Hypertens. (Greenwich) (1999);1(1): pp. 41-47.
    PubMed
  27. McFarlane S I, Sowers J R, Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease , J. Clin. Endocrinol. Metab. (2003);88(2): pp. 516-523.
    Crossref | PubMed
  28. Pitt B, Zannad F, Remme W J, Cody R, Castaigne A, Perez A et al., The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , N. Engl. J. Med. (1999);341(10): pp. 709-717.
    Crossref | PubMed
  29. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al., Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , N. Engl. J. Med. (2003);348(14): pp. 1,309-1,321.
    Crossref | PubMed
  30. Modan M, Halkin H, Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension , Diabetes Care (1991);14(6): pp. 470-487.
    Crossref | PubMed
  31. DeFronzo R A, Ferrannini E, Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease , Diabetes Care (1991);14(3): pp. 173-194.
    Crossref | PubMed
  32. DeFronzo R A, The effect of insulin on renal sodium metabolism. A review with clinical implications , Diabetologia (1981);21(3): pp. 165-171.
    PubMed
  33. Anderson E A, Hoffman R P, Balon T W, Sinkey C A, Mark A L, Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans , J. Clin. Invest. (1991);87(6): pp. 2,246-2,252.
    Crossref | PubMed
  34. Berne C, Fagius J, Pollare T, Hjemdahl P, The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects , Diabetologia (1992);35(9): pp. 873-879.
    Crossref | PubMed
  35. Rowe J W, Young J B, Minaker K L, Stevens A L, Pallotta J, Landsberg L, Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man , Diabetes (1981);30(3): pp. 219-225.
    Crossref | PubMed
  36. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M, Insulin Induces Upregulation of Vascular AT1 Receptor Gene Expression by Posttranscriptional Mechanisms , Circulation (1998);98(22): pp. 2,453-2,460.
    Crossref | PubMed
  37. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H, Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity , Diabetes (1999);48(4): pp. 821-827.
    Crossref | PubMed
  38. Raji A, Seely E W, Bekins S A, Williams G H, Simonson D C, Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients , Diabetes Care (2003);26(1): pp. 172-178.
    Crossref | PubMed
  39. Dengel D R, Hagberg J M, Pratley R E, Rogus E M, Goldberg A P, Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men , Metabolism (1998);47(9): pp. 1,075-1,082.
    Crossref | PubMed
  40. Wassertheil-Smoller S, Blaufox M D, Oberman A S, Langford H G, Davis B R, Wylie-Rosett J, The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension , Arch. Intern. Med. (1992);152(1): pp. 131-136.
    Crossref | PubMed
  41. Sacks F M, Svetkey L P, Vollmer W M, Appel L J, Bray G A, Harsha D et al., Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet , N. Engl. J. Med. (2001);344(1): pp. 3-10.
    Crossref | PubMed
  42. Halbert J A, Silagy C A, Finucane P, Withers R T, Hamdorf P A, Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials , Eur. J. Clin. Nutr. (1999);53(7): pp. 514-522.
    Crossref | PubMed
  43. Whelton S P, Chin A, Xin X, He J, Effect of Aerobic Exercise on Blood Pressure: A Meta-Analysis of Randomized, Controlled Trials , Ann. Intern. Med. (2002);136(7): pp. 493-503.
    Crossref | PubMed
  44. Whaley-Connell A, Sowers J R, Hypertension management in type 2 diabetes mellitus: recommendations of the Joint National Committee VII , Endocrinol. Metab. Clin. North Am. (2005);34(1): pp. 63-75.
    Crossref | PubMed
  45. Treatment of Hypertension in Adults With Diabetes , Diabetes Care (2003);26(90,001): pp. 80S-82.
    Crossref
  46. Chobanian A V, Bakris G L, Black H R, Cushman W C, Green L A, Izzo J L, Jr et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report , JAMA (2003);289(19): pp. 2,560-2,571.
    Crossref | PubMed
  47. Arauz-Pacheco C, Parrott M A, Raskin P, The Treatment of Hypertension in Adult Patients With Diabetes , Diabetes Care (2002);25(1): pp. 134-147.
    Crossref | PubMed
  48. Ravid M, Lang R, Rachmani R, Lishner M, Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study , Arch. Intern. Med. (1996);156(3): pp. 286-289.
    Crossref | PubMed
  49. Bakris G L, Smith A C, Richardson D J, Hung E, Preston R, Goldberg R et al., Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study , J. Hum. Hypertens. (2002);16(3): pp. 185-191.
    Crossref | PubMed
  50. Bakris G L, Weir M R, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , Arch. Intern. Med. (2000);160(5): pp. 685-693.
    Crossref | PubMed
  51. Lindholm L H, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O, Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) , J. Hypertens. (2003);21(8): pp. 1,563-1,574.
    Crossref | PubMed
  52. Pfeffer M A, Swedberg K, Granger C B, Held P, McMurray J J, Michelson E L et al., Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , Lancet (2003);362(9,386): pp. 759-766.
    Crossref | PubMed
  53. Lindholm L H, Ibsen H, Borch-Johnsen K, Olsen M H, Wachtell K, Dahlof B et al., Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , J. Hypertens. (2002);20(9): pp. 1,879-1,886.
    Crossref | PubMed
  54. Yusuf S, Pfeffer M A, Swedberg K, Granger C B, Held P, McMurray J J et al., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , Lancet (2003);362(9,386): pp. 777-781.
    Crossref | PubMed
  55. Julius S, Kjeldsen S E, Weber M, Brunner H R, Ekman S, Hansson L et al., Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , Lancet (2004);363(9,426): pp. 2,022-2,031.
    Crossref | PubMed
  56. Yusuf S, From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis , Am. J. Cardiol. (2002);89(2A): pp. 18A-25A; discussion pp. 25A-26A.
    Crossref | PubMed
  57. Gerstein H C, Yusuf S, Holman R, Bosch J, Pogue J, Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial , Diabetologia (2004);47(9): pp. 1,519-1,527.
    Crossref | PubMed
  58. Califf R M, Insulin resistance: a global epidemic in need of effective therapies , Eur. Heart J. Suppl. (2003);5(suppl_C): pp. C13-18.
    Crossref
  59. Scheen A J, Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system , Drugs (2004);64(22): pp. 2,537-2,565.
    Crossref | PubMed
  60. Group UKPDS, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , BMJ (1998);317(7,160): pp. 703-713.
    Crossref | PubMed
  61. Group UKPDS, Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , BMJ (1998);317(7160): pp. 713-720.
    Crossref | PubMed
  62. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R et al., Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension: A Randomized, Controlled Trial , Ann. Intern. Med. (1997);126(12): pp. 955-959.
    Crossref | PubMed
  63. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , JAMA (2002);288(23): pp. 2,981-2,997.
    Crossref | PubMed
  64. Curb J D, Pressel S L, Cutler J A, Savage P J, Applegate W B, Black H et al., Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension , Systolic Hypertension in the Elderly Program Cooperative Research Group, JAMA (1996);276(23): pp. 1,886-1,892.
    Crossref | PubMed
  65. Birkenhager W H, Staessen J A, Gasowski J, de Leeuw P W, Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial , J. Nephrol. (2000);13(3): pp. 232-237.
    PubMed
  66. Hansson L, Zanchetti A, Carruthers S G, Dahlof B, Elmfeldt D, Julius S et al., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , HOT Study Group, Lancet (1998);351(9,118): pp. 1,755-1,762.
    Crossref | PubMed
  67. Poulter N R, Calcium antagonists and the diabetic patient: a response to recent controversies , Am. J. Cardiol. (1998);82(9B): pp. 40R-41R.
    Crossref | PubMed